ICICI Securities Ltd | Retail Equity Research Revenues declined 16% YoY to | 6653 crore (I-direct estimate: | 6907 crore) due to 38% YoY decline in the US to | 2125 crore (Idirect estimate: | 2189 crore) due to the high base of gGleevec and gBenicar and dismal performance of Taro's sales. India sales grew 6% YoY to | 2125 crore (I-direct estimate: | 2189 crore) EBITDA margins declined to 21.8% (I-direct estimate: 21.5%) against 31.0% in Q3FY17, due to high base, pricing pressure in the US and decline in Taro's margins (42.5% vs. 60.2% in Q3FY17)...